SCHEMBL22249281

SCHEMBL22249281

CNCCc1cc(O)c(O)c(O)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.64
HIF1A Q16665 2/20 0.64
HSD17B10 Q99714 2/20 0.64
TP53 P04637 1/20 0.64
CYP1A2 P05177 1/20 0.64
ALOX15 P16050 1/20 0.64
TSHR P16473 1/20 0.64
NFKB1 P19838 1/20 0.64
MAPK1 P28482 1/20 0.64
THPO P40225 1/20 0.64
KDM4E B2RXH2 2/20 0.62
ALDH1A1 P00352 2/20 0.62
LMNA P02545 2/20 0.62
HPGD P15428 2/20 0.62
BLM P54132 2/20 0.62
GMNN O75496 1/20 0.62
GFER P55789 1/20 0.62
PMP22 Q01453 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12582139 0.80 TMEM97 (0.52) MAPTHIF1AHSD17B10TP53CYP1A2
SCHEMBL13093762 0.79 TMEM97 (0.61) MAPTHIF1AHSD17B10TP53CYP1A2
SCHEMBL22249384 0.78 MAPT (0.41) MAPTHIF1AHSD17B10TP53CYP1A2
Deoxiepinephrine SCHEMBL67772 0.78 MAPT (1.00) MAPTHIF1AHSD17B10TP53CYP1A2
Deoxiepinephrine SCHEMBL29379200 0.78 MAPT (1.00) MAPTHIF1AHSD17B10TP53CYP1A2
SCHEMBL10979039 0.78 TAAR1 (0.50) MAPTHIF1AHSD17B10TP53CYP1A2
SCHEMBL14849307 0.78 TAAR1 (0.50) MAPTHIF1AHSD17B10TP53CYP1A2
SCHEMBL22249279 0.77 ADRB2 (0.44) MAPTHIF1AHSD17B10TP53CYP1A2
Deoxiepinephrine SCHEMBL31364234 0.77 MAPT (1.00) MAPTHIF1AHSD17B10TP53CYP1A2
Deoxiepinephrine SCHEMBL7438678 0.77 MAPT (0.96) MAPTHIF1AHSD17B10TP53CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230147416-A1 HYALURONIC ACID DERIVATIVE AND USE THEREOF AMTIXBIO CO., LTD. (KR) 2023-05-11 US disclosed
US-20200230288-A1 HYDROGEL USING, AS SUBSTRATE, HYALURONIC ACID DERIVATIVE MODIFIED WITH GALLOL GROUP AND USE THEREOF AMTIXBIO CO., LTD. (KR) 2020-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147416-A1 HYALURONIC ACID DERIVATIVE AND USE THEREOF CD44, HAO2, HAAO MAPT 4540/4885HIF1A 843/4885HSD17B10 489/4885
US-20200230288-A1 HYDROGEL USING, AS SUBSTRATE, HYALURONIC ACID DERIVATIVE MODIFIED WITH GALLOL GROUP AND USE THEREOF CD44, PGA5, HAO2 MAPT 4300/4885HIF1A 710/4885HSD17B10 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.